REGN15505 Combinations for Prostate and Kidney Cancers

This trial investigates a new cancer drug, REGN15505, to evaluate its effectiveness alone and in combination with other drugs for treating advanced prostate and kidney cancers. The goal is to discover new methods to enhance the immune system's ability to combat these cancers. The trial will assess side effects, treatment efficacy, and optimal dosing. Men with prostate cancer that has spread and progressed despite treatment, and individuals with clear-cell type kidney cancer that has spread and not responded to previous treatments, may qualify for participation. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

Previous studies have collected safety information for the drugs tested in this trial. Research shows that REGN15505 is being carefully monitored for side effects when used alone or with other drugs. Some studies have examined its tolerability, but detailed safety results are still being gathered.

Cemiplimab, combined with REGN15505 in one part of the trial, has been used in other studies. These studies often examine how the body processes the drug and any potential side effects. For example, earlier trials of cemiplimab combined with other drugs showed no severe immune-related side effects in some patients who did not respond to treatment.

For the combination of REGN15505 and REGN4336, studies have focused on REGN4336 alone, examining its safety and efficacy. The exact side effects are still under evaluation, but ongoing research aims to learn more about its safety.

Researchers are excited about the treatments involving REGN15505 for prostate and kidney cancers because they introduce novel combinations and mechanisms that differ from current options like hormone therapy and chemotherapy. REGN15505 alone acts as a monotherapy, targeting specific cancer pathways directly. In combination with Cemiplimab, it leverages an immune checkpoint inhibitor to enhance the immune response against cancer cells. The pairing with REGN4336 brings together two novel agents that may work synergistically to inhibit tumor growth more effectively. These innovative approaches have the potential to offer more targeted and effective treatment options compared to traditional therapies.

Research has shown that REGN15505 helps the body's immune cells locate and destroy cancer cells by connecting with specific proteins on the cancer cells' surface. In this trial, some participants may receive REGN15505 alone, which has shown potential to activate the immune system against cancer. Another group will receive a combination of REGN15505 and REGN4336, which demonstrated strong anti-cancer effects in lab tests. Additionally, some participants will receive REGN15505 with cemiplimab, as cemiplimab is known to enhance the immune system's ability to fight cancer. While these findings are promising, more research is needed to fully understand the effectiveness of these treatments in people.³⁶⁷⁸⁹